Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
09/2005
09/22/2005WO2005087721A2 Compounds as inhibitors of hepatitis c virus ns3 serine protease
09/22/2005WO2005087266A1 Combination therapy for inhibition of platelet aggregation
09/22/2005WO2005087258A1 Use of botulinum toxin for preparing a drug for preventing hair growth
09/22/2005WO2005087257A1 Remedy for repairing cartilage tissue having crosslinked gelatin gel as support
09/22/2005WO2005087256A1 Use of corticotroph-derivced glycoprotein hormone to treat liver steatosis
09/22/2005WO2005087255A2 Method of optimizing treatment with interferon-tau
09/22/2005WO2005087254A2 Pharmaceutical compositions comprising interferon-tau
09/22/2005WO2005087253A2 Interferon-beta for anti-virus therapy for respiratory diseases
09/22/2005WO2005087252A1 Use of dm43 and its fragments as matrix metalloproteinases inhibitor
09/22/2005WO2005087251A1 Compositions and methods for inhibiting abnormal cell growth
09/22/2005WO2005087250A1 Therapeutic administration of the scrambled anti-angiogenic peptide c16y
09/22/2005WO2005087249A1 Protease inhibitor and preventives or remedies for diseases
09/22/2005WO2005087207A1 Compositions and methods for the treatment of depression and other affective disorders
09/22/2005WO2005087201A1 Hydrogel microspheres with improved release profile
09/22/2005WO2005086970A2 Novel multipeptide regimen for the treatment of autistic spectrum, behavioral, emotional and visceral inflammation/autoimmune disorders
09/22/2005WO2005086947A2 Method for inhibiting immune complex formation in a subjetc
09/22/2005WO2005086915A2 Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
09/22/2005WO2005086827A2 Methods of assessing the need for and the effectiveness of therapy with antioxidants
09/22/2005WO2005086825A2 Methods and compositions for treatment of diseases associated with aberrant microsatellite expansion
09/22/2005WO2005086800A2 Cell-penetrating socs polypeptides that inhibit cytokine-induced signaling
09/22/2005WO2005086798A2 Improved interleukin-2 muteins
09/22/2005WO2005086773A2 A method for delivering therapeutic proteins to the intradermal compartment
09/22/2005WO2005086751A2 Combinatorial interleukin-2 muteins
09/22/2005WO2005086684A2 Method for modulating, regulating and/or stabilizing angiogenesis
09/22/2005WO2005086674A2 Brhf1 as a cancer diagnostic marker
09/22/2005WO2005068498A3 Human therapeutic cells secreting nerve growth factor
09/22/2005WO2005067962A3 Composition derived from milk goat comprising growth factors and oligosaccharides
09/22/2005WO2005052139A3 Method of inducing memory b cell development and terminal differentiation
09/22/2005WO2005046594A3 Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders
09/22/2005WO2005044981A3 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
09/22/2005WO2005038006A8 Chimeric metabotropic glutamate receptors and uses thereof
09/22/2005WO2005034844A3 Exosite-directed thrombin inhibitors
09/22/2005WO2005030258A3 Small molecule compositions and methods for increasing drug efficiency using compositions thereof
09/22/2005WO2005025503A3 A composition and method of treatment for urogenital conditions
09/22/2005WO2005016248A3 A novel antiproliferative factor and methods of use
09/22/2005WO2005007069A3 Soft gel formulations for saquinavir
09/22/2005WO2004101606A3 Novel peptides that bind to the erythropoietin receptor
09/22/2005WO2004060265A3 Eye-drop vaccine containing copolymer 1 for therapeutic immunization
09/22/2005WO2003086278A3 Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions
09/22/2005WO2003065997A3 Anti-infarction molecules
09/22/2005WO2000075279A3 Nucleotide sequences for gene regulation and methods of use thereof
09/22/2005US20050209666 Electrical devices and anti-scarring agents
09/22/2005US20050209665 Electrical devices and anti-scarring agents
09/22/2005US20050209308 Coniosulfides and their derivatives, processes for preparing them, and their use as pharmaceuticals
09/22/2005US20050209212 2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid; carbapenems derivatives containing a carboxy substituted phenyl group; broad spectrum antibacterial activity; good stability; beta-lactamases inhibitors; improvement over imipenem
09/22/2005US20050209182 Inhibits bacterial subtilisn type serine protease CylA activity; siRNA, antisense, and enzymatic nucleic acid molecules that can modulate the expression of CylA genes
09/22/2005US20050209177 Combined use of genes that block oncogenic cell signalling pathways and chemotherapeutic and or radiotherapeutic agents
09/22/2005US20050209174 Especially conjugating derivatives of paclitaxel, cholesterol, camptothecin, and rhodamine123 to transferrins, side effect reduction
09/22/2005US20050209164 Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
09/22/2005US20050209163 (R)-2-acetamido-N-benzyl-3-methoxy-propionamide; O-methyl-N-acetyl-D-serine-m-fluorobenzylamide; epilepsy and other CNS disorders
09/22/2005US20050209162 Methods for monitoring IL-18
09/22/2005US20050209161 Drugs for treatment of inflammation/blood brain barrier degradation;administering to a subject in need of such treatment, a pharmaceutically effective amount of a peptide antagonist of zonulin, wherein the peptide antagonist binds to a zonula occludens toxin receptor
09/22/2005US20050209160 Protein kinase C peptides for use in withdrawal
09/22/2005US20050209159 Effectors of dipeptidyl peptidase IV for topical use
09/22/2005US20050209158 Inhibitors of the ATPase activity of Hsp90; antitumor drugs
09/22/2005US20050209157 Cause stimulation and proliferation of human fibroblasts and lymphocytes; antibacterial, antifungal, anticancer; containing phenylalanine, leucine, alanine, and lysine amino acid residues
09/22/2005US20050209156 Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
09/22/2005US20050209155 IGF-binding protein-derived peptide or small molecule
09/22/2005US20050209154 Containing high-molecular vWF multimers and being free from low-molecular vWF molecules and proteolytic vWF degradation products; chromatographic purification of Factor VIII or a Factor VIII/vWF-complex, admixing a purified high-molecular fraction of vWF molecules; hemophilia A, von Willebrand Disease
09/22/2005US20050209153 Acid-labile subunit (ALS) of insulin-like growth factor binding protein complex
09/22/2005US20050209152 Polypeptoid pulmonary surfactants
09/22/2005US20050209151 Administering a ligand peptide for a G protein-coupled receptor protein for regulating the secretion of corticotropin-releasing hormones; hypoaldosteronism, hypocortisolemia, secondary or chronic hypoadrenocorticism, Addison's disease, adrenal dysfunction, or obesity
09/22/2005US20050209150 Compositions and methods for inhibiting abnormal cell growth
09/22/2005US20050209149 Factor IXa for the treatment of bleeding disorders
09/22/2005US20050209148 Methods of treating obesity or diabetes using NT-4/5
09/22/2005US20050209147 Containing a transport domain, a linker and a RhoA domain; antiinflammatory agents in the inhibition of leukocyte adhesion and migration, antiarthritic, antiproliferative, antimetastasis, and antifibrotic agents
09/22/2005US20050209146 Administering bifunctional molecules containing a drug moiety and presenter protein ligand for therapy
09/22/2005US20050209145 Self-assembling peptide amphiphiles and related methods for growth factor delivery
09/22/2005US20050209144 Protein formulations
09/22/2005US20050209143 Protein from horn fly saliva that disrupts hemostasis
09/22/2005US20050209142 Administering Thyrocalcitonin, Calcitonin, Exendin or a derivative or analog thereof; neurodegenerative disorders, ischemic disorders, neurological traumas, and learning and memory disorders; stem cell transplants; Parkinson's, Alzheimer's, Huntington's Diseases, Multiple Sclerosis
09/22/2005US20050209141 Mast cell-derived renin
09/22/2005US20050209140 Methods of controlling axonal growth
09/22/2005US20050209139 Cancer Treatment Using C-Type Natriuretic Peptides
09/22/2005US20050209138 Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
09/22/2005US20050209136 Method for stimulating connective tissue growth or wound healing
09/22/2005US20050209135 Etherification of an N-protected-2-carboxyl-4-hydroxypyrrolidine with a 4-halo-quinolone, amidation with a 1-amino-2-vinylcylcopropane, deprotecting the ring nitrogen, amidation with a 7-octenoic acid, ring closing metathesis with 2nd generation Hoveyda's catalyst; one pot process; Hepatitis C viricides
09/22/2005US20050209134 Novel depsipeptide compound
09/22/2005US20050209133 Glycoprotein synthesis
09/22/2005US20050209132 Cross-linked glycopeptide-cephalosporin antibiotics
09/22/2005US20050209131 Composition containing peptides complexed with a copper ion
09/22/2005US20050209130 Compositions and methods for treatment of rosacea
09/22/2005US20050209128 Statins, especially (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, as nerve conduction velocity or nerve blood flow enhancers in combination with an aldose reductase inhibitor, an ACE inhibitor or an Angiotensin II antagonist
09/22/2005US20050208659 Using adenoviral transformation/transfection to transfer cyclin and cyclin dependent kinase genes into nucleus of differentiated cells; regenerative medicine and tissue engineering
09/22/2005US20050208640 Using transferase polypeptide in diagnosis, prevention and treatment of cell proliferative disorders; cosmetics; nutraceuticals
09/22/2005US20050208626 SGIP peptides
09/22/2005US20050208622 50 human secreted proteins
09/22/2005US20050208621 Nucleotide sequences coding serine threonine kinase for identifying modulators for prevention and treatment of inflammation, endocrine and nervous system disorders
09/22/2005US20050208619 29 human secreted proteins
09/22/2005US20050208618 Nucleotide sequences coding thrombospondin metalloproteinase-like-thrombospondin type 1 (ITGL-TSP) protein for identifying modulators to treat and prevent diabetes, restenosis, alzheimer's, cell proliferative and cardiovascular disorders
09/22/2005US20050208617 Human-like glycoproteins; for hydrolysis of oligosaccharide substrates for N-glycan processing in secretory pathway
09/22/2005US20050208612 Transglutaminase has intrinsic kinase activity
09/22/2005US20050208610 Method of producing an anticoagulation effect
09/22/2005US20050208602 Using placental proteins as tools for detection, prevention, and/or treatment of diabetes, muscular and cell proliferative disorders
09/22/2005US20050208591 Antibodies to chemokine alpha-6
09/22/2005US20050208587 Fab 4E10/KGND crystal complex for use in preparing viricidal agents; rational drug design
09/22/2005US20050208584 Using modified thanatos-associated-protein-1 (THAP1) for treatment and prevention of inflammation, arthritis and inflammatory bowel diseases
09/22/2005US20050208583 Detection of autoantibodies to cytokeratin 18 protein in patients with bronchial asthma and chronic rhinitis, and its applications including a kit for diagnosing bronchial asthma and chronic rhinitis comprising mammalian cytokeratin 18 protein
09/22/2005US20050208580 Novel protein and method for producing the protein
09/22/2005US20050208578 Isolated human aminoacylase, nucleic acid molecules encoding human aminoacylase, and uses thereof
1 ... 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 ... 3163